PE20170693A1 - Derivados de imidazol pentaciclicos fusionados - Google Patents
Derivados de imidazol pentaciclicos fusionadosInfo
- Publication number
- PE20170693A1 PE20170693A1 PE2017000544A PE2017000544A PE20170693A1 PE 20170693 A1 PE20170693 A1 PE 20170693A1 PE 2017000544 A PE2017000544 A PE 2017000544A PE 2017000544 A PE2017000544 A PE 2017000544A PE 20170693 A1 PE20170693 A1 PE 20170693A1
- Authority
- PE
- Peru
- Prior art keywords
- fused
- pentaciclic
- imidazole derivatives
- compounds
- difluorometoxy
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- HYZJCKYKOHLVJF-SFIIULIVSA-N 1H-benzimidazole Chemical group C1=CC=C2N[11CH]=NC2=C1 HYZJCKYKOHLVJF-SFIIULIVSA-N 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- MBVAHHOKMIRXLP-UHFFFAOYSA-N imidazo[1,2-a]pyrazine Chemical group C1=CN=CC2=NC=CN21 MBVAHHOKMIRXLP-UHFFFAOYSA-N 0.000 abstract 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical group C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical class [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE IMIDAZOL PENTACICLICOS FUSIONADOS DE FORMULA (I) DONDE -X-Q- REPRESENTA -O-, -O-C(O)-, -C(O)-O-, ENTRE OTROS; Z ES METILENO; E ES 1H-BENZIMIDAZOL, IMIDAZO[1,2-a]PIRIDINA O IMIDAZO[1,2-a]PIRAZINA OPCIONALMENTE SUSTITUIDOS; R5 Y R8 SON CADA UNO H, HALOGENO, HIDROXI, CN, ENTRE OTROS; R6 Y R7 SON CADA UNO H, HALOGENO, TRIFLUOROMETILO, ENTRE OTROS; R12 ES H O C1-C6 ALQUILO. SON COMPUESTOS PREFERIDOS: (7R,14R)-1-(DIFLUOROMETOXI)-10-FLUORO-11-[2-(2-HIDROXIPROPAN-2-IL)PIRIMIDIN-5-IL]-6,7-DIHIDRO-7,14-METANOBENCIMIDAZO[1,2-b][2,5]BENZODIAZOCIN-5(14H)-ONA; (7R,14R)-1-(DIFLUOROMETOXI)-11-[2-(2-HIDROXIPROPAN-2-IL)PIRIMIDIN-5-IL]-6,7-DIHIDRO-7,14-METANOBENCIMIDAZO[1,2-b][2,5]BENZODIAZOCIN-5(14H)-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE TNF ALFA HUMANO SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS, TRASTORNOS NEUROLOGICOS Y NEURODEGENERATIVOS
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290299 | 2014-10-03 | ||
| EP15162641 | 2015-04-07 | ||
| EP15171036 | 2015-06-08 | ||
| PCT/EP2015/072868 WO2016050975A1 (en) | 2014-10-03 | 2015-10-02 | Fused pentacyclic imidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170693A1 true PE20170693A1 (es) | 2017-06-13 |
Family
ID=54238452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000544A PE20170693A1 (es) | 2014-10-03 | 2015-10-02 | Derivados de imidazol pentaciclicos fusionados |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10202405B2 (es) |
| EP (1) | EP3201196B1 (es) |
| JP (1) | JP6629847B2 (es) |
| KR (1) | KR102442235B1 (es) |
| CN (1) | CN107108672B (es) |
| AP (1) | AP2017009809A0 (es) |
| AU (1) | AU2015326798B2 (es) |
| BR (1) | BR112017006669B1 (es) |
| CA (1) | CA2962826C (es) |
| CL (1) | CL2017000787A1 (es) |
| CO (1) | CO2017003331A2 (es) |
| CR (1) | CR20170167A (es) |
| DK (1) | DK3201196T3 (es) |
| EA (1) | EA032839B1 (es) |
| EC (1) | ECSP17027306A (es) |
| ES (1) | ES2885432T3 (es) |
| GT (1) | GT201700044A (es) |
| HR (1) | HRP20211605T1 (es) |
| HU (1) | HUE056133T2 (es) |
| IL (1) | IL251147B (es) |
| LT (1) | LT3201196T (es) |
| MA (1) | MA40770B1 (es) |
| MX (1) | MX2017004201A (es) |
| MY (1) | MY181019A (es) |
| PE (1) | PE20170693A1 (es) |
| PH (1) | PH12017500414B1 (es) |
| PL (1) | PL3201196T3 (es) |
| RS (1) | RS62423B1 (es) |
| SG (1) | SG11201701796XA (es) |
| SI (1) | SI3201196T1 (es) |
| TN (1) | TN2017000083A1 (es) |
| TW (1) | TWI719949B (es) |
| UA (1) | UA120764C2 (es) |
| UY (1) | UY36341A (es) |
| WO (1) | WO2016050975A1 (es) |
| ZA (1) | ZA201701946B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI719949B (zh) * | 2014-10-03 | 2021-03-01 | 比利時商Ｕｃｂ生物製藥公司 | 稠合五環咪唑衍生物 |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| UY36628A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CN109219609B (zh) | 2016-04-01 | 2022-02-01 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合六环咪唑衍生物 |
| US10654861B2 (en) | 2016-04-01 | 2020-05-19 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
| WO2017167996A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| EA201892153A1 (ru) | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |
| GB201620948D0 (en) | 2016-12-09 | 2017-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110461842A (zh) * | 2017-03-15 | 2019-11-15 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
| SI3615534T1 (sl) * | 2017-04-25 | 2022-01-31 | UCB Biopharma SRL | Derivati zlitega pentacikličnega imidazola kot modulatorji delovanja TNF |
| JP7429694B2 (ja) * | 2018-10-24 | 2024-02-08 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレータとしての縮合五環式イミダゾール誘導体 |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| US20240247014A1 (en) * | 2022-11-23 | 2024-07-25 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024223740A1 (en) | 2023-04-26 | 2024-10-31 | Sanofi | Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449649A3 (en) | 1990-03-30 | 1992-09-02 | Arizona Board Of Regents, Arizona State University | Antineoplastic quinones and methods of using same |
| FR2832711B1 (fr) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| BRPI0408477A (pt) | 2003-03-10 | 2006-04-04 | Pfizer | compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| KR101941420B1 (ko) | 2011-06-20 | 2019-01-23 | 스페로 트리넴, 인코포레이티드 | 자이라제 및 토포이소머라제 억제제의 인산에스테르 |
| CN104428293B (zh) * | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
| CN104619709B (zh) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| US9266883B2 (en) | 2013-10-25 | 2016-02-23 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SI3925607T1 (sl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi |
| TWI719949B (zh) * | 2014-10-03 | 2021-03-01 | 比利時商Ｕｃｂ生物製藥公司 | 稠合五環咪唑衍生物 |
-
2015
- 2015-10-02 TW TW104132631A patent/TWI719949B/zh active
- 2015-10-02 MA MA40770A patent/MA40770B1/fr unknown
- 2015-10-02 MX MX2017004201A patent/MX2017004201A/es unknown
- 2015-10-02 EP EP15771976.6A patent/EP3201196B1/en active Active
- 2015-10-02 CN CN201580053711.8A patent/CN107108672B/zh active Active
- 2015-10-02 HU HUE15771976A patent/HUE056133T2/hu unknown
- 2015-10-02 EA EA201790734A patent/EA032839B1/ru not_active IP Right Cessation
- 2015-10-02 PL PL15771976T patent/PL3201196T3/pl unknown
- 2015-10-02 UY UY0001036341A patent/UY36341A/es not_active Application Discontinuation
- 2015-10-02 ES ES15771976T patent/ES2885432T3/es active Active
- 2015-10-02 CA CA2962826A patent/CA2962826C/en active Active
- 2015-10-02 LT LTEPPCT/EP2015/072868T patent/LT3201196T/lt unknown
- 2015-10-02 SI SI201531711T patent/SI3201196T1/sl unknown
- 2015-10-02 HR HRP20211605TT patent/HRP20211605T1/hr unknown
- 2015-10-02 CR CR20170167A patent/CR20170167A/es unknown
- 2015-10-02 MY MYPI2017701132A patent/MY181019A/en unknown
- 2015-10-02 US US15/513,357 patent/US10202405B2/en active Active
- 2015-10-02 PE PE2017000544A patent/PE20170693A1/es unknown
- 2015-10-02 JP JP2017518131A patent/JP6629847B2/ja active Active
- 2015-10-02 KR KR1020177011958A patent/KR102442235B1/ko active IP Right Grant
- 2015-10-02 AP AP2017009809A patent/AP2017009809A0/en unknown
- 2015-10-02 RS RS20211235A patent/RS62423B1/sr unknown
- 2015-10-02 DK DK15771976.6T patent/DK3201196T3/da active
- 2015-10-02 UA UAA201702002A patent/UA120764C2/uk unknown
- 2015-10-02 SG SG11201701796XA patent/SG11201701796XA/en unknown
- 2015-10-02 TN TN2017000083A patent/TN2017000083A1/en unknown
- 2015-10-02 WO PCT/EP2015/072868 patent/WO2016050975A1/en active Application Filing
- 2015-10-02 BR BR112017006669-6A patent/BR112017006669B1/pt active IP Right Grant
- 2015-10-02 AU AU2015326798A patent/AU2015326798B2/en active Active
-
2017
- 2017-03-06 PH PH12017500414A patent/PH12017500414B1/en unknown
- 2017-03-07 GT GT201700044A patent/GT201700044A/es unknown
- 2017-03-14 IL IL251147A patent/IL251147B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01946A patent/ZA201701946B/en unknown
- 2017-03-31 CL CL2017000787A patent/CL2017000787A1/es unknown
- 2017-04-06 CO CONC2017/0003331A patent/CO2017003331A2/es unknown
- 2017-05-03 EC ECIEPI201727306A patent/ECSP17027306A/es unknown
-
2018
- 2018-12-14 US US16/220,847 patent/US10906919B2/en active Active
-
2020
- 2020-11-24 US US17/102,790 patent/US11912721B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170693A1 (es) | Derivados de imidazol pentaciclicos fusionados | |
| SG11201907095UA (en) | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
| PH12019500676A1 (en) | Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators | |
| CL2016002836A1 (es) | Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame). | |
| TR201909614T4 (tr) | Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri. | |
| TR201908447T4 (tr) | Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri. | |
| UY35935A (es) | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 | |
| NI201600152A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| BR112016011484A2 (pt) | Derivados de imidazopirimidina como moduladores de atividade de tnf | |
| MX370000B (es) | Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3. | |
| MX2019007084A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. | |
| PE20081612A1 (es) | Analogos de las pterinas | |
| BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112016011794A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| NZ751509A (en) | Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one | |
| PE20160532A1 (es) | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim | |
| BR112016012997A2 (pt) | Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf | |
| MX2019007073A (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak. | |
| PE20160026A1 (es) | Compuestos heterociclicos como agentes para control de plagas | |
| BR112016012243A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| PE20151332A1 (es) | Compuestos de azabencimidazol | |
| BR112016013012A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| GT201400213A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| BR112019005969A2 (pt) | inibidores seletivos de jak1 inovadores e usos dos mesmos | |
| PE20170295A1 (es) | Compuestos de imidazopiridazina |